RAPT Therapeutics’ (RAPT) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright restated their neutral rating on shares of RAPT Therapeutics (NASDAQ:RAPT) in a report issued on Monday,Benzinga reports. HC Wainwright also issued estimates for RAPT Therapeutics’ Q4 2024 earnings at ($0.58) EPS, FY2024 earnings at ($2.56) EPS, Q2 2025 earnings at ($0.66) EPS, Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($0.63) EPS and FY2025 earnings at ($2.61) EPS.

A number of other research analysts also recently issued reports on RAPT. Wells Fargo & Company cut their price target on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a report on Tuesday, November 12th. JPMorgan Chase & Co. lowered shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. UBS Group reduced their price objective on RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating for the company in a research note on Monday, September 9th. Stifel Nicolaus reissued a “hold” rating and set a $2.00 target price (down previously from $7.00) on shares of RAPT Therapeutics in a report on Wednesday, November 13th. Finally, Piper Sandler downgraded RAPT Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $8.00 to $2.00 in a report on Monday, November 11th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $9.50.

RAPT Therapeutics Price Performance

NASDAQ:RAPT opened at $1.23 on Monday. The company has a market cap of $43.00 million, a price-to-earnings ratio of -0.44 and a beta of 0.33. RAPT Therapeutics has a 1 year low of $1.00 and a 1 year high of $27.35. The stock’s 50 day simple moving average is $1.80 and its two-hundred day simple moving average is $2.61.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09. As a group, analysts anticipate that RAPT Therapeutics will post -2.73 EPS for the current year.

Institutional Investors Weigh In On RAPT Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in shares of RAPT Therapeutics by 21.2% in the first quarter. Vanguard Group Inc. now owns 2,492,850 shares of the company’s stock valued at $22,386,000 after purchasing an additional 436,629 shares during the period. Point72 Asset Management L.P. grew its stake in shares of RAPT Therapeutics by 176,725.0% during the second quarter. Point72 Asset Management L.P. now owns 707,300 shares of the company’s stock worth $2,157,000 after purchasing an additional 706,900 shares in the last quarter. Cubist Systematic Strategies LLC increased its holdings in shares of RAPT Therapeutics by 826.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 295,241 shares of the company’s stock valued at $900,000 after acquiring an additional 263,372 shares during the last quarter. Acadian Asset Management LLC increased its stake in RAPT Therapeutics by 4,183.3% in the second quarter. Acadian Asset Management LLC now owns 467,182 shares of the company’s stock valued at $1,424,000 after purchasing an additional 456,275 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in RAPT Therapeutics during the 2nd quarter worth $108,000. Hedge funds and other institutional investors own 99.09% of the company’s stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.